Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
CHRS 
Coherus BioSciences Inc (CHRS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/23/2025: CHRS (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.67
1 Year Target Price $5.67
| 3 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.43% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 159.55M USD | Price to earnings Ratio 2.4 | 1Y Target Price 5.67 |
Price to earnings Ratio 2.4 | 1Y Target Price 5.67 | ||
Volume (30-day avg) 7 | Beta 0.96 | 52 Weeks Range 0.71 - 1.89 | Updated Date 12/24/2025 |
52 Weeks Range 0.71 - 1.89 | Updated Date 12/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.55 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 55.8% | Operating Margin (TTM) -364.99% |
Management Effectiveness
Return on Assets (TTM) -10.26% | Return on Equity (TTM) 33.11% |
Valuation
Trailing PE 2.4 | Forward PE 41.15 | Enterprise Value 18250418 | Price to Sales(TTM) 0.57 |
Enterprise Value 18250418 | Price to Sales(TTM) 0.57 | ||
Enterprise Value to Revenue 0.07 | Enterprise Value to EBITDA 0.2 | Shares Outstanding 120871013 | Shares Floating 112990223 |
Shares Outstanding 120871013 | Shares Floating 112990223 | ||
Percent Insiders 12.44 | Percent Institutions 43.43 |
Upturn AI SWOT
Coherus BioSciences Inc
Company Overview
History and Background
Coherus BioSciences, Inc. was founded in 2010 with the mission to develop and commercialize high-quality, affordable biosimil products. Significant milestones include the FDA approval and launch of its first biosimilar, Udenycau00ae (pegfilgrastim-cbkn), in 2019, and subsequent approvals for its other biosimilar products. The company has evolved by strategically building a portfolio of biosimil candidates targeting significant market opportunities in oncology and immunology, and adapting its commercialization strategies.
Core Business Areas
- Biosimil Product Development and Commercialization: Coherus focuses on developing and bringing to market biosimil versions of complex biologic drugs that are nearing or have recently lost patent exclusivity. This involves extensive research, clinical trials, and regulatory submissions, followed by a robust commercial launch strategy.
- Oncology and Immunology Therapeutics: The company's primary therapeutic areas of focus are oncology and immunology, where there is a substantial need for more affordable treatment options.
Leadership and Structure
Coherus BioSciences Inc. is led by a seasoned management team with expertise in the biopharmaceutical industry. Key leadership roles typically include a Chief Executive Officer (CEO), Chief Medical Officer (CMO), Chief Financial Officer (CFO), and various heads of departments overseeing research and development, commercial operations, and regulatory affairs. The organizational structure is designed to support the lifecycle of biosimilar products from development through commercialization.
Top Products and Market Share
Key Offerings
- Competitors: Amgen (Neulastau00ae),Sandoz (Ziextenzou00ae),Pfizer (Nyvepriau2122)
- Description: A biosimilar to Neulastau00ae (pegfilgrastim), used to reduce the incidence of febrile neutropenia in patients with cancer receiving chemotherapy. Coherus has achieved significant market share with Udenycau00ae, facing competition from Amgen's Neulastau00ae, and other biosimilar entrants like Sandoz's Ziextenzou00ae and Pfizer's Nyvepriau2122.
- Market Share Data: Not publicly disclosed as a precise percentage, but Coherus has reported strong unit sales and revenue contributions from Udenycau00ae.
- Product Name: Udenycau00ae (pegfilgrastim-cbkn)
- Competitors: AbbVie (Humirau00ae),Amgen (Amjevitau00ae),Boehringer Ingelheim (Cyltezou00ae),Novartis (Hyrimozu00ae)
- Description: A biosimilar to Humirau00ae (adalimumab), used to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and Crohn's disease. Launched in the US in 2023, it competes with AbbVie's Humirau00ae and other adalimumab biosimil manufacturers.
- Market Share Data: As a newer entrant, market share is still developing and is not yet substantial compared to the originator.
- Product Name: Yusimryu00ae (adalimumab-aqvh)
- Competitors: Genentech/Roche (Avastinu00ae),Amgen/Samsung Bioepis (Ayvakitu00ae),Pfizer (Tavalisseu00ae)
- Description: A biosimilar to Avastinu00ae (bevacizumab), used in the treatment of certain types of cancer. Coherus launched Imbozu00ae in the US in 2023.
- Market Share Data: Market share is still developing.
- Product Name: Imbozu00ae (bevacizumab-dyyb)
Market Dynamics
Industry Overview
The biosimilar market is a rapidly growing segment of the biopharmaceutical industry. It is characterized by increasing regulatory support, patent expirations of blockbuster biologics, and a strong demand for cost-effective treatment alternatives. Key trends include the expanding pipeline of biosimilar candidates, evolving reimbursement policies, and increasing physician and patient acceptance.
Positioning
Coherus BioSciences Inc. is positioned as a leading biosimilar company in the United States, focusing on developing and commercializing high-value biosimil products. Its competitive advantages include a strong regulatory and manufacturing expertise, a strategic focus on key therapeutic areas, and an experienced commercial team. The company aims to capture significant market share by offering affordable alternatives to high-cost biologic therapies.
Total Addressable Market (TAM)
The total addressable market for biosimil biologics is substantial and projected to grow significantly in the coming years, driven by the patent expiration of numerous blockbuster drugs. While specific TAM figures vary by therapeutic area and drug class, it is estimated to be in the hundreds of billions of dollars globally. Coherus is positioned to capture a portion of this TAM by focusing on widely prescribed biologics with significant market potential.
Upturn SWOT Analysis
Strengths
- Strong portfolio of approved biosimilar products with significant market potential.
- Experienced management team with deep expertise in biopharmaceutical development and commercialization.
- Established manufacturing and supply chain capabilities.
- Successful track record of FDA approvals and market launches.
- Focus on high-value therapeutic areas like oncology and immunology.
Weaknesses
- Reliance on a limited number of key products for revenue.
- Intense competition in the biosimilar market from both established players and new entrants.
- Potential for pricing pressure and reimbursement challenges.
- Need for continuous innovation and pipeline development to maintain growth.
- Past financial performance has shown volatility and at times losses.
Opportunities
- Increasing number of biologic drugs nearing patent expiration, creating new biosimilar opportunities.
- Growing global demand for affordable healthcare solutions.
- Expansion into new geographic markets.
- Potential for strategic partnerships and collaborations.
- Advancements in biosimilar development and manufacturing technologies.
Threats
- Regulatory hurdles and delays in biosimilar approval processes.
- Aggressive pricing strategies from originator companies and competitors.
- Changes in healthcare policies and reimbursement landscapes.
- Intellectual property litigation and challenges.
- Emergence of novel biologics or alternative therapies that could reduce demand for biosimil products.
Competitors and Market Share
Key Competitors
- Amgen Inc. (AMGN)
- AbbVie Inc. (ABBV)
- Pfizer Inc. (PFE)
- Sandoz International GmbH (part of Novartis AG)
- Boehringer Ingelheim GmbH
Competitive Landscape
Coherus faces intense competition from large pharmaceutical companies with established biosimilar divisions and from dedicated biosimilar manufacturers. Its advantages lie in its focused strategy and efficient development, while disadvantages could include smaller scale compared to giants like Amgen or Pfizer, and reliance on market acceptance of its products against established originators and other biosimil competitors.
Growth Trajectory and Initiatives
Historical Growth: Historically, Coherus has focused on building its biosimilar pipeline and achieving regulatory approvals. Growth has been driven by the successful launch of Udenycau00ae and subsequent product introductions. The company has shown a trajectory of increasing revenue year-over-year as its product portfolio expands.
Future Projections: Future growth is projected to be driven by the continued uptake of its existing biosimil products and the successful launch of new candidates. Analyst estimates often focus on revenue growth fueled by market penetration and expansion into new indications or therapeutic areas. Profitability is a key future projection as the company matures.
Recent Initiatives: Recent initiatives by Coherus have included the launch of Yusimryu00ae and Imbozu00ae in the US, expanding its commercial footprint. The company has also focused on strategic partnerships and business development to strengthen its pipeline and market access.
Summary
Coherus BioSciences Inc. is a promising player in the biosimilar market, demonstrating strong growth with its key products like Udenycau00ae. The company has successfully navigated the complex regulatory landscape and launched multiple biosimil products. Its primary strengths lie in its product portfolio and experienced management. However, it faces significant competition and the inherent challenges of achieving profitability in a price-sensitive market. Coherus needs to vigilantly manage its expenses, continue to innovate, and effectively expand its market share to ensure long-term success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations Filings (SEC EDGAR)
- Industry Analyst Reports
- Financial News Outlets
- Biopharmaceutical Market Data Providers
Disclaimers:
This JSON output is generated based on publicly available information and is for informational purposes only. It does not constitute financial advice or an endorsement of any investment. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Market share data and competitor analysis are estimations and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Coherus BioSciences Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2014-11-06 | Chairman, President & CEO Mr. Dennis M. Lanfear | ||
Sector Healthcare | Industry Biotechnology | Full time employees 158 | Website https://www.coherus.com |
Full time employees 158 | Website https://www.coherus.com | ||
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.